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Abstract
Background: Huntington Disease (HD) is a neurodegenerative disorder in which caspase activation and cleavage
of substrates, including the huntingtin protein, has been invoked as a pathological mechanism. Specific changes in
caspase-2 (casp2) activity have been suggested to contribute to the pathogenesis of HD, however unique casp2
cleavage substrates have remained elusive. We thus utilized mice completely lacking casp2 (casp2-/-) to examine
the role played by casp2 in the progression of HD. This ‘substrate agnostic’ approach allows us to query the effect
of casp2 on HD progression without pre-defining proteolytic substrates of interest.
Results: YAC128 HD model mice lacking casp2 show protection from well-validated motor and cognitive features
of HD, including performance on rotarod, swimming T-maze, pre-pulse inhibition, spontaneous alternation and
locomotor tasks. However, the specific pathological features of the YAC128 mice including striatal volume loss and
testicular degeneration are unaltered in mice lacking casp2. The application of high-resolution magnetic resonance
imaging (MRI) techniques validates specific neuropathology in the YAC128 mice that is not altered by ablation of
casp2.
Conclusions: The rescue of behavioral phenotypes in the absence of pathological improvement suggests that
different pathways may be operative in the dysfunction of neural circuitry in HD leading to behavioral changes
compared to the processes leading to cell death and volume loss. Inhibition of caspase-2 activity may be
associated with symptomatic improvement in HD.
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Background
Huntington disease (HD) is a neurodegenerative disor-
der characterized by progressive motor, cognitive and
psychiatric deficits [1] caused by an expanded poly-glu-
tamine tract in the huntingtin (HTT) protein [2]. Neu-
ropathologically, HD is characterized by early loss of
medium spiny neurons (MSNs) in the striatum, accom-
panied by gliosis and eventual progressive neuronal loss
throughout the brain [3].
Caspases are a family of proteases initially described to
play critical roles in apoptotic cell death [4], whose non-
apoptotic cellular functions are increasingly realized [5].
HTT has been shown to be a substrate in vitro for cas-
pases-1,2,3 and -6 [6-9]. A number of additional pro-
teins whose mutation causes neurodegeneration are also
caspase substrates, including the amyloid precursor pro-
tein [10-12], tau [13], atrophin-1 [9], ataxin-3 [9],
ataxin-7 [14] and the androgen receptor [9].
The commonality of caspase cleavage of neurodegenera-
tive disease proteins could reflect their degradative clear-
ance during cell death. Alternatively, these cleavage events
could mediate apoptotic signaling, as is the case for bid
[15], XIAP [16] and the caspases themselves [17]. Support-
ing the latter hypothesis, mutation of obligate aspartate
residues in the caspase recognition regions of HTT has
established that cleavage at amino acid 586, a caspase-6 site
* Correspondence: mrh@cmmt.ubc.ca
2Centre for Molecular Medicine and Therapeutics, Child and Family Research
Institute, Department of Medical Genetics, University of British Columbia,
Vancouver, V5Z 4H4, Canada
Full list of author information is available at the end of the article
Carroll et al. Molecular Neurodegeneration 2011, 6:59
http://www.molecularneurodegeneration.com/content/6/1/59
© 2011 Carroll et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.in vitro, is crucial for the development of HD symptoms in
a mouse model [18-20]. Analogous rescue is observed in
mutant APP-transgenic mice resistant to caspase cleavage
at aspartate-664 [21,22]. Further, prevention of caspase pro-
cessing of both atrophin-1 [23] and ataxin-7 [14] reduces
toxicity in vitro. These experiments suggest that caspase-
mediated cleavage of neurodegenerative disease proteins
plays a role in the development of these conditions.
Caspase-2 (casp2) has been implicated in both Alzhei-
mer’s and Huntington disease. Dominant-negative casp2
constructs rescue mutant HTT-induced toxicity in
rodent neurons, and total casp2 levels are increased in
vulnerable neurons in human patient post-mortem tis-
sue [6]. Furthermore, antisense to casp2 protects multi-
ple neuronal cell lines from Aß1-42 induced toxicity
[24-26]. Despite these disease associations, being the
second mammalian caspase cloned [27,28] and its high
degree of evolutionary conservation [29] the role of
casp2 in vivo has remained unresolved.
While HTT itself is cleaved by casp2 at aspartate-552
in vitro [6], this event is not crucial for development of
HD because mutating this site does not confer protec-
tion from HD symptoms in a mouse model [18], and
constitutive cleavage at this site is observed in control,
as well as diseased, brains [7]. However, experiments in
rodent neurons with dominant-negative casp2 con-
structs support the idea that activity of casp2 may con-
tribute to mutant-HTT induced toxicity [6]. While
casp2 cleavage of HTT is thus unlikely to cause pathol-
ogy in HD, other activities of casp2 may contribute to
signs and symptoms of HD.
Very few casp2 cleavage substrates have been
reported: casp2 [30], golgin-160 [31], aII-spectrin [32],
protein kinase C (delta) [33], and Bid [34]. Of these
events, only golgin-160 cleavage is uniquely catalyzed
by casp2 [31]. Furthermore, the reagents commonly
used as inhibitors and markers of casp2 activity based
on the binding between VDVAD pseudo-substrate and
active casp2 enzyme have been conclusively shown to
be nonspecific [35], limiting their use in complex
samples.
To examine the role of casp2 in HD we thus under-
took a ‘substrate agnostic’ approach. Rather than focus-
ing on particular potential cleavage events, we studied
the development of HD symptoms in the well-validated
YAC128 murine model of HD [36-38] when bred to
casp2 -/- mice [39] to determine whether developmental
and complete lack of casp2 may in some way modify
the phenotype of HD, without relying on proxy makers
for caspase activation.
Results
Casp2 mRNA and HTT protein levels in the brain
Casp2 has been described as transcriptionally upregu-
lated in the striatum of the YAC72 mouse model of HD
[6] and total casp2 immunoreactivity is increased in the
brain of HD patients with significant striatal pathology
[6]. To more directly examine caspase-2 transcription,
we examined publically avai l a b l em i c r o a r r a yd a t a[ 4 0 ]
from early-stage (Vonsattel grade 0-2) human HD stria-
tal tissue. This reveals no change in casp2 mRNA levels
in the striatum of HD patients (table 1). Levels of tran-
scripts reduced in HD, such as HMG-CoA reductase
[41], are reduced in HD patients in this population, sup-
porting the robustness of the dataset (table 1).
Consistent with this human data, quantitative real-
time PCR (QRT-PCR) of striatal casp2 mRNA demon-
strates that wild type (WT) and YAC128 mice have
equivalent levels throughout their life spans (table 1,
two-way ANOVA, Genotype: F(1,27) = 0.073, p = 0.79;
Age: F(3,27) = 2.48, p = 0.082; Interaction: F(3,27) =
2.71, p = 0.065). Thus, in both a rigorously characterized
animal model of HD, as well as patient material, we see
no evidence for transcriptional upregulation of casp2 in
affected tissues at a time when both the mice and
humans are displaying symptoms of HD.
We then considered whether levels of full-length
mutant HTT could be altered by expression of casp2-/-.
Table 1 Casp2 expression in the striatum of YAC128 mice and human HD patients
Species Age (M) Disease
Stage*
Gene Expression, HD/Control SEM t-value p-value
Mouse 3 Casp2 .704 .063 1.78 > 0.05
Mouse 6 Casp2 1.15 .11 0.56 > 0.05
Mouse 9 Casp2 1.20 .12 0.71 > 0.05
Mouse 12 Casp2 1.01 .12 0.08 > 0.05
Human** 0-2 Casp2 0.996 -0.14 > 0.05
Human** 0-2 HMGCR 0.739 -5.04 < 0.001
Human striatal casp2 mRNA levels were extracted from publically available sources of microarray data (Affymetrix HG-U133A/B probe set 208050_s_at, HDBase.
org-originally described in [66]). Mouse striatal casp2 levels were determined using QRT-PCR at 3, 6, 9 and 12 months of age. Casp2 is not upregulated in the
striatum of aging YAC128 mice or human HD patients.
* Vonsattel neuropathological score at time of death [3]
** Human data extracted from [40]
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repeats (1C2, Millipore MAB1574), we performed wes-
tern blots with cortices of 12-month old YAC128 and
casp2-/-;YAC128 mice. There was no effect of genotype
on full-length mutant huntingtin levels (data not shown,
t(4) = 0.12, p = 0.91). We have previously demonstrated
that the aa586 caspase-6 fragment of HTT is uniquely
linked to toxicity in the YAC128 model of HD [18-20].
We determined the levels of the aa586 caspase-6 frag-
ment in the cortex of 12 month old YAC128 and
casp2-/-;YAC128 mice, using the same western blots.
These blots reveal no effect of genotype on aa586 frag-
ment levels (data not shown, t(4) = 0.36, p = 0.74).
Casp2 -/- mice are protected from motor and cognitive
symptoms of HD
The YAC128 murine model of HD robustly recapitu-
lates many of the signs and symptoms of HD [37,38]. In
order to examine the effect of casp2 on HD onset and
progression, we bred heterozygous YAC128 [38] mice to
a casp2 -/- [39] and WT background.
From two months of age YAC128 mice demonstrate
performance deficits when first exposed to a fixed-speed
(18 RPM) 2-minute rotarod running task [37]. In this
cohort, at 4 months of age, no effect of casp2 ablation is
observed in WT mice on the time to first fall during 2-
minute training sessions Figure 1A, gray and black
lines). As described [37], YAC128 mice perform signifi-
cantly worse than WT mice, an effect which is rescued
in casp2-/-;YAC128 mice (Figure 1A, red and pink lines,
linear mixed effects model YAC128 F(1,109) = 7.74, p =
0.0064; casp2 F(1,109) = 1.43, p = 0.23; Interaction F
(1,109) = 5.36, p = 0.023). The mean time to first fall
across all 9 trials is 68% of WT levels in the YAC128
mice, but 94% of WT levels in the casp2-/-;YAC128
mice, showing that casp2-/-;YAC128 mice are
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Figure 1 Casp2-/- mice are protected from rotarod learning and accelerating rotorod deficits in the YAC128 mice. A-B) Naïve mice were
trained at 4 months of age on a fixed speed (18 RPM) rotorod; 9 trials of 2 minutes each were conducted over three days. The time to first fall
and the number of falls during each trial was recorded. Casp2-/- mice are unaffected on this task, compared to WT littermates as measured by
time to first fall, while YAC128 mice show significant impairment that is rescued in casp2-/-;YAC128 mice (linear mixed effects model YAC128 F
(1,109) = 7.74, p = 0.0064; casp2 F(1,109) = 1.43, p = 0.23; Interaction F(1,109) = 5.36, p = 0.023) or number of total falls (linear mixed effects
model YAC128 F(1,109) = 9.45, p = 0.0026; casp2 F(1,109) = 1.09, p = 0.30; Interaction F(1,109) = 3.97, p = 0.049). Data represent mean +/- SEM.
N = 33 WT mice, 28 YAC128 mice, 28 casp2-/- mice and 24 casp2-/-;YAC128. C) Mice were tested on an accelerating rotorod (5-40 RPM) at 4, 8
and 12 months. Each mouse performed 3 5-minute trials and the mean of three trials recorded. YAC128 mice perform worse than WT littermates
on this task (i-two-way ANOVA, YAC128 F(1,51) = 23.07, p < 0.0001, age F(2,51) = 77.92, p < 0.0001; interaction F(2,51) = 1.61, p = 0.20), while
casp2-/-;YAC128 mice do not perform significantly worse than casp2-/- littermates (ii-two-way ANOVA, YAC128 F(1,45) = 2.39, p = 0.13, age F
(2,45) = 18.0, p < 0.0001; interaction F(2,45) = 0.11, p = 0.89). Data represent mean +/- SEM. N = 33 WT mice, 28 YAC128 mice, 28 casp2-/- mice
and 24 casp2-/-;YAC128.
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Examination of the total number of falls during the
training session validates the specific impairment of the
YAC128 mice, which is again ameliorated in the
casp2-/-;YAC128 mice (Figure 1B, linear mixed effects
model YAC128 F(1,109) = 9.45, p = 0.0026; casp2 F
(1,109) = 1.09, p = 0.30; Interaction F(1,109) = 3.97, p =
0.049).
After training, mice were tested on a 5-minute accel-
erating rotarod (5-40 RPM) task at 4, 8 and 12 months
of age. As previously shown, YAC128 mice perform sig-
nificantly worse than littermates on this task (Figure 1C
i, two-way ANOVA, YAC128 F(1,102) = 23.07, p <
0.0001, Age F(2,102) = 77.92, p < 0.0001, Interaction F
(2,102) = 1.61, p = 0.24). In mice lacking casp2, this
effect is ameliorated (Figure 1C ii, two-way ANOVA,
Genotype F(1,90) = 2.4, p = 0.13, Age F(2,90) = 18.0, p
< 0.0001, Interaction F(2,90) = 0.11, p = 0.89). At 12
months of age, YAC128 latency to fall is reduced by
39% compared to WT mice (95.8 sec. vs. 157.6 sec,
respectively). Casp2-/-;YAC128 mice remain on the
rotarod for an average of 154.6 seconds, 98% of WT
levels, suggesting complete rescue of this phenotype.
In addition to motor impairment, YAC128 mice
demonstrate clear cognitive and psychiatric deficits ana-
logous to those seen in human HD patients [37,42,43].
To probe perseverative behaviors, we used a previously
validated swimming T-maze task [37]. At 12 months of
age there is no difference in swimming speed between
any of the genotypes in the current study, and all four
genotypes of mice learned to reach a submerged plat-
form equally well during 12 training runs over 4 days
(Figure 2, left side, two-way repeated measures ANOVA,
genotype: F(3,58) = 0.56, p = 0.64). On day 5, the plat-
form was switched to the opposite arm of the swimming
t-maze and YAC128 mice require significantly longer to
reach the new platform location, while casp2-/-;YAC128
mice perform similar to WT mice (Figure 2A, right side,
two-way repeated measures ANOVA, genotype: F(3,58)
= 2.90, p = 0.043, Bonferroni post-test trial 1, Casp2-/-;
YAC128 vs. YAC128, t = 2.78, p < 0.05). This is primar-
ily due to increased perseveration during the first rever-
sal trial-the YAC128 mice re-enter the previously
c o r r e c ta r mo ft h em a z em o r ef r e q u e n t l yt h a nY A C 1 2 8
mice lacking casp2 (Figure 2B, repeated measures two-
way ANOVA Bonferroni post-hoc tests indicated).
These data suggest that YAC128 mice lacking casp2 are
protected from loss of cognitive flexibility-a cardinal
early feature of psychiatric disturbances in HD [44,45].
To extend our understanding of the cognitive defects
underlying this deficiency, we examined the spontaneous
alternation of mice in a T-maze [46]. In this spatial
memory task mice are released at the base of the T-
maze and allowed to choose an arm to explore. When
re-exposed to the maze, normal mice recall the pre-
viously visited arm of the T-maze and prefer to investi-
gate the novel arm 79% of the time. YAC128 mice
perform near chance in this task, visiting the new arm
o ft h em a z eo n l y5 3 %o ft h et i m e .B o t hc a s p 2 - / -a n d
casp2-/-;YAC128 mice perform similarly to WT mice
choosing the new arm 77% and 73% of the time respec-
tively (Figure 2C).
HD patients show reduced pre-pulse inhibition (PPI)
[47], as do YAC128 mice [37]. At 12 months of age star-
tle amplitude in response to a 120dB noise is equivalent
in all examined mice (one-way ANOVA, genotype: F
(3,37) = 0.36, p = 0.78). In a PPI paradigm with a back-
ground noise + 2dB, 4dB or 16dB warning tone the
YAC128 mice have reduced PPI compared to WT mice
(Figure 3B, 2dB Genotype F(3,39) = 4.49, p = 0.0089;
4dB Genotype F(3,38) = 3.07, p = 0.04; 16dB Genotype
F(3,37) = 2.25, p = 0.10; Newman-Keuls post-hoc test p-
values indicated). Lower intensity pre-pulses led to more
obvious deficits in the YAC128 mice, in agreement with
previously published results [37]. This effect was amelio-
rated in casp2-/-;YAC128 mice, who had normalized PPI
compared to YAC128 mice, suggesting that sensorimo-
tor gating defects are corrected in YAC128 mice lacking
casp2.
YAC128 mice are hypoactive during exploration of an
open field after about 6 months of age [38]. This loco-
motor phenotype is rescued in the casp2-/-;YAC128
mice at 7 months of age (Figure 4A, one way ANOVA F
(3,67) = 4.30, p = 0.0079, Newman-Keuls post-hoc tests
indicated). In addition to their hypoactive phenotype,
the YAC128 mice show anxiety by spending less time in
the center of the open field arena, and entering the cen-
ter zone less frequently [48]. This phenotype is also
ameliorated in the casp2-/-;YAC128 mice (Figure 4B,
right, one way ANOVA F (3,67) = 5.73, p = 0.0015,
Newman-Keuls post-hoc tests indicated).
Casp2-/- mice are not protected from pathological
features of HD
Brain weight is the simplest measure of neurodegenera-
tion, and is decreased in the YAC128 mice [38]. In the
present cohort, forebrain weight is reduced in the
YAC128 mice, an effect which is not ameliorated by the
absence of casp2 (Figure 5A, linear mixed effects model,
YAC128 F(1,39) = 4.5, p = 0.040; casp2 F(1,39) = 0.432,
p = 0.52). Male YAC128 mice and human HD patients
also have specific testicular degeneration [49], a pheno-
type which is also not affected by the absence of casp2
(Figure 5B, linear mixed effects model, YAC128: F(1,18)
= 5.70, p = 0.028; Casp2: F(1,18) = 0.10, p = 0.75). Like
HD patients, YAC128 mice have progressive specific
striatal volume decreases [38,50]. Using stereological
techniques we observe reduced striatal volume in the
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Page 4 of 12YAC128 mice that is not ameliorated in the casp2-/-;
YAC128 mice (Figure 5C, two-way ANOVA YAC128: F
(3,86) = 6.04, p = 0.016; casp2 F(3,86) = 0.17, p = 0.69;
Interaction F(1,88) = 0.02, p = 0.88).
To gain more detailed information on YAC128 neuro-
pathology, we have developed and described magnetic
resonance imaging (MRI) techniques to generate volu-
metric data for a number of CNS structures [50-53]. These
techniques allow the complete three-dimensional delinea-
tion of structures, avoiding artificial truncation due to
tissue processing limitations. Measurements are conducted
on brains in situ in the skull, minimizing processing and
handling artifacts. Also, using atlas based MRI techniques
it is possible to simultaneously determine volumes for a
large number of structures, rather than limiting analyses to
pre-determined regions of interest. Direct comparison of
MRI and stereological approaches to measuring striatal
volume in the YAC128 mice has shown that while the
volume loss detected by each technique is the same, MRI is
more accurate and therefore powerful [50,54].
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Figure 2 Casp2-/- mice are protected from cognitive symptoms of HD in the YAC128 mouse. A) Mice were trained in a swimming T-maze
to find a submerged platform in one arm of the maze. Acquisition time of the platform location does not differ between genotypes during the
first 12 trials (two-way repeated measures ANOVA genotype: F(3,638) = 0.56, p = 0.64). Before trial 1 of the reversal phase on day 5, the platform
was switched to the opposite arm of the T-maze. Time to the platform in its new location differed by genotype across the 4 trials (two-way
repeated measures ANOVA, genotype: F(3,147) = 2.90, p = 0.043). YAC128 mice take significantly longer to reach the platform on the first trial
than Casp2-/-;YAC128 mice (19.5 seconds vs. 10.86 seconds, Bonferroni t = 3.205, p < 0.01). Data represent mean +/- SEM. N = 33 WT mice, 28
YAC128 mice, 28 casp2-/- mice and 24 Casp2-/-;YAC128 mice. B) Increased time to platform in the YAC128 mice was primarily due to increased
perseveration during the first trial. YAC128 mice re-entered the previously correct arm more frequently than Casp2-/-;YAC128 mice (two-way
repeated measures ANOVA Trial F(3,174) = 10.19, p < 0.0001; YAC128 F(3,174) = 2.04, p = 0.12; Interaction F(9,174) = 1.42, p = 0.18; Bonferroni
post-hoc test significance indicated). N = 21 WT mice, 28 YAC128 mice, 17 casp2-/- mice and 24 Casp2-/-;YAC128 mice. C) YAC128;casp2-/- are
rescued from deficits in a T-maze spontaneous alternation task. 7-month old Mice were exposed to a T-maze with a divider forcing them to
choose one arm, which they were restrained to for 1 minute. After this familiarization trial, the mice re-entered the T-maze and their arm choice
recorded. WT mice prefer the novel arm of the maze 79% of the time, while YAC128 mice only choose the novel arm 53% of the time. Casp2-/-
and YAC128;casp2-/- choose the novel arm 77% and 73% of the time, similar to WT mice. N = 15 WT mice, 21 YAC128 mice, 17 casp2-/- mice
and 15 Casp2-/-;YAC128 mice.
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Page 5 of 12MRI data was acquired post-mortem, at twelve
months of age-the same mice were used for both beha-
vioral and MRI experiments. Total brain volume, as
determined by MRI, was reduced in the YAC128 mice
and not rescued in the casp2-/- mice, though reductions
observed did not reach significance (Figure 6A, left,
two-way ANOVA YAC128: F(1,39) = 3.10, p = 0.086;
casp2: F(1,39) = 0.02, p = 0.88; Interaction F(1,39) =
0.38, p = 0.54). MRI-detected striatal volume is specifi-
cally reduced in the YAC128 mice, and not affected by
casp2 expression (Figu r e6 A ,t w o - w a yA N O V A
YAC128: F(1,39) = 13.14, p = 0.0008, casp2: F(1,39) =
0.02, p = 0.85; Interaction: F(1,39) = 0.38, p = 0.54).
Other brain structures, such as the thalamus, show atro-
phy in the YAC128 mice [54,50], and human patients
[55]. This atrophy was validated in the current cohort
and was not affected by casp2 expression (Figure 6A,
two-way ANOVA, YAC128: F(1,39) = 11.41, p = 0.0017;
casp2: F(1,39) = 2.704, p = 0.11; Interaction: F(1,39) =
0.09, p = 0.76).
MRI-detected volumes are valuable measures of tissue
atrophy because they can be normalized to total brain
volume. These “brain normalized” values highlight speci-
fic regions of atrophy and preservation, by correcting for
changes in brain volume. We have shown that regions
of both atrophy (the striatum) and preservation (the cer-
ebellum) can be observed with these measures in the
YAC128 mice [50]. In agreement with the stereological
data, striatal volume, when considered as a fraction of
total brain volume, is reduced in the YAC128 mice, and
not rescued in the casp2-/-;YAC128 mice (Figure 6B,
Bonferroni post-hoc tests indicated). Analogously, the
cerebellar cortex is increased in relative volume, due to
its preservation in the face of HD-induced atrophy. This
cerebellar preservation is not altered in the casp2-/-;
YAC128 mice (Figure 6B, Bonferroni post-hoc tests
indicated). These results validate the specific pathologi-
cal tissue loss in the YA128 mice, the use of MRI to
ascertain these losses, and clearly demonstrate that the
absence of casp2 is not associated with amelioration of
this loss.
Discussion
The primary finding of the current study is that casp2-/-
mice are protected from behavioral and cognitive fea-
tures of HD in the YAC128 model. It is remarkable that
every behavioral and cognitive feature of HD examined
is completely rescued in the absence of caspase-2. How-
ever, pathological phenotypes of HD including specific
striatal volume loss and testicular degeneration are not
rescued in the casp-2-/- mice.
Caspase-2 transcription
This work expands our understanding of the activation
of casp2 in HD. An earlier report suggested that tran-
scriptional up-regulation, secondary to BDNF loss, could
explain increases in casp2 levels in HD [6]. The data
presented here do not support this hypothesis-human
microarray data indicates that striatal casp2 levels are
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Figure 4 Casp2-/- mice are protected from locomotor
symptoms of HD in the YAC128 mouse. At 7 months of age,
YAC128 mice display decreased locomotor activity and increased
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Mean="+”, horizontal bars = quartiles. N = 15 WT mice, 21 YAC128
mice, 17 casp2-/- mice and 15 Casp2-/-;YAC128 mice. Post-hoc
Newman-Keuls genotype comparisons “*” indicates p < 0.05.
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Figure 3 Casp2-/-;YAC128 mice are protected from pre-pulse inhibition deficits. Mice were tested for pre-pulse inhibition at 12 months of
age. YAC128 mice show reduced PPI, compared to littermates, while casp2-/-;YAC128 mice do not (one-way ANOVA 2dB Genotype F(3,39) =
4.49, p = 0.0089; 4dB Genotype F(3,38) = 3.07, p = 0.04; 16dB Genotype F(3,37) = 2.25, p = 0.10; Newman-Keuls post-hoc test p-values indicated).
Mean="+”, horizontal bars = quartiles. N = 7 WT mice, 12 YAC128 mice, 9 casp2-/- mice and 12 Casp2-/-;YAC128 mice. Post-hoc Bonferroni
genotype comparisons “*” indicates p < 0.05.
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Page 6 of 12normal in early stage HD patients. Additionally, striatal
casp2 mRNA levels in YAC128 HD mice are equivalent
to WT levels during the development of HD-like beha-
vioral changes. Thus, increased casp2 transcription is
unlikely to contribute to the development of HD.
Caspase-2 -/- mice are protected from motor and
cognitive features of HD
Casp2-/- mice are protected from motor and cognitive
deficits seen in the YAC128 model of HD. Consistent
with previous reports, we show that the YAC128 mice
have deficits during the learning phase of the rotarod
task at 4 months of age [37]. This learning deficit is
completely reversed in the YAC128 mice lacking casp2,
who are also protected from progressive motor impair-
ment on the previously learned task. This demonstrates
that casp2-/-;YAC128 mice are protected from both
cognitive and motor aspects of this task.
Data from the pre-pulse inhibition, swimming T-maze
and spontaneous alternation tasks presented here are
consistent with the cognitive flexibility deficits pre-
viously observed in the YAC128 mice [37]. All these
tasks were performed significantly better by casp2-/-;
YAC128 mice, relative to YAC128 mice. This suggests
that YAC128 mice lacking casp2 are better able to mod-
ify their behavior in response to environmental demands
than normal YAC128 mice. Specific deficits in beha-
vioral flexibility are a key feature of the cognitive defects
observed in human HD patients [56,57], and improve-
ment of these symptoms in casp2-/-;YAC128 mice sup-
ports the idea that casp2 inhibition may have impact on
neural function, leading to symptomatic benefit.
Casp2-/- mice are not protected from pathological
features of HD
Despite their protection from behavioral and cognitive
symptoms, the volume loss observed in the YAC128 mice
in structures such as the striatum and thalamus is not ame-
liorated by the absence of casp2. In the periphery, patholo-
gical atrophy of the testes is also not ameliorated in
casp2-/-;YAC128 mice. The improved performance of the
casp2-/-;YAC128 mice on behavioral tasks in the face of
this pathological tissue loss suggests that neuronal circuits
mediating disease relevant behavior are capable of augmen-
tation leading to symptomatic benefit. These experiments
demonstrate that loss of volume is not sufficient to cause
all motor and cognitive features of HD in mice.
Previous interventions in the YAC128 mice have
shown dissociation between neuropathological and
behavioral endpoints. Symptomatic treatment with
cystamine results in neuroprotection without affecting
behavioral symptoms of HD [58]. Conversely, sympto-
matic treatment with ethyl-eicosapentaenoic acid pro-
vides relief from motor symptoms of HD, without
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Figure 5 Casp2-/- mice are not protected from pathology. A-B)
Fixed forebrain and testes weight in 12-month-old mice. YAC128
mice show forebrain atrophy that is not rescued by the absence of
casp2 (summary statistics for two-way ANOVA indicated). Mean="+”,
horizontal bars = quartiles. N = 9 WT mice, 11 YAC128 mice, 9
casp2-/- mice, 14 Casp2-/-;YAC128 mice. C) Striatal volume, as
determined by stereology, is reduced in YAC128 mice and not
affected by caspase-2 expression. Mean="+”, horizontal bars =
quartiles, isolated dots = outliers. Factorial ANOVA F/p-values
indicated. N = 19 WT mice, 25 YAC128 mice, 21 casp2-/- mice, 22
Casp2-/-;YAC128 mice.
Carroll et al. Molecular Neurodegeneration 2011, 6:59
http://www.molecularneurodegeneration.com/content/6/1/59
Page 7 of 12altering neuropathological features [59]. These results, in
conjunction with the current study, demonstrate that
some aspects of pathological development are dissoci-
able from tissue atrophy in HD. This dissociability of
pathological and behavioral symptoms highlights the
potential need for different approaches to treatment at
different stages of illness, and also for different signs
and symptoms. The value of symptomatic therapy is
clear; tetrabenazine, the only FDA-approved drug for
HD, is used as an anti-chorea agent with no claim of
disease modification [60].
Conclusions
Casp2-/- mice are protected from a number of beha-
vioral features of HD in the YAC128 mouse model. This
protection is seen in a number of paradigms, including
motor learning, motor coordination, cognitive flexibility,
spatial learning, sensorimotor gating and locomotor
behavior. Casp2-/- mice are not protected from patholo-
gical signs of HD including testicular atrophy and
regionally specific brain atrophy as assayed by stereology
and magnetic resonance imaging techniques. These find-
ings lend weight to the concept that symptomatic
improvement is possible in HD even in the face of unal-
tered pathology.
A secondary goal of the current study was to objec-
tively evaluate the usefulness of casp2 as a drug target
in HD. There are several caveats to careful interpreta-
tion of these data. First, in these mice casp2 expression
is absent throughout development, rather than being
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Page 8 of 12postnatally suppressed, as with a drug. Also, we have
completely ablated, rather than reduced, the activities of
casp2. Therefore it is difficult to extrapolate these find-
ings with a genetic model to the effect of a drug, but
these beneficial effects clearly warrant additional investi-
gation. The single mutation underlying HD has a large
array of effects on cells, and if the mutant HTT protein
cannot be directly targeted for therapy, it may be neces-
sary to target multiple aberrant processes to provide
effective therapy for HD. Based on findings here, casp2
inhibition coupled with neuroprotective therapy may be
an effective strategy to combat behavioral, cognitive and
neuropathological features of HD.
Methods
Mice and breeding
Caspase-2-/- mice [39] were obtained on the C57Bl/6
strain, and backcrossed for at least 7 generations to the
FVB/NJ strain before being used for experiments or
bred to the YAC128 mouse. YAC128 (line 53) mice [38]
were maintained on the FVB/NJ strain. Caspase-2+/-;
YAC128+/- breeders were intercrossed and pups of
appropriate genotypes selected from the resultant pro-
geny, to ensure subject mice were littermates. The
resulting mice (wild type, casp2-/-, YAC128 and
casp2-/-;YAC128) were genotyped for the rd allele
which causes progressive retinal degeneration and blind-
ness in the FVBN/J strain-all mice carried the FVBN/J
rd mutant allele. Mice were genotyped for the YAC128
transgene and housed as previously described [38], and
all animal experiments were conducted in accordance
with protocols approved by the University of British
Columbia Committee on Animal Care.
Quantitative Real-time PCR (QRT-PCR)
Total RNA was extracted from dissected striata, frozen
and stored at -80C using the RNeasy mini kit (Qiagen,
74104). cDNA was prepared using 250 ng total RNA
and the superscript-III first-strand synthesis kit with
oligo-dT priming (Invitrogen, 11752-050). Primers used
included mouse casp2 forward: 5’-GAATGAACCTTAT
CGGGCATAACT-3’ and reverse: 5’-GATGACGGGT-
GATAGTGTGAGACA-3’. Mouse actin forward: 5’-
ACGGCCAGGTCATCACTATTG-3’ and reverse: 5’-
CAAGAAGGAAGGCTGGAAAAGA-3’.Q R T P C Rw a s
conducted using SYBR Green PCR master mix (Applied
Biosystems, 4309155) in the ABI7500 instrument
(Applied Biosystems) using the absolute quantification
standard curve method.
Behavioral assays
Mice were single housed in microisolator cages with a
12 h light/dark cycle. Mice were randomly coded and
the experimenter was blind to genotype. Motor
coordination and learning were examined using an
accelerating rotarod (UGO Basile, Comerio, Italy). For
training, naïve 4-month-old mice were given three trials
of 2 minutes on a fixed speed (18 RPM) task per day for
three days (9 trials total). The inter-trial interval was 2
hours. Mice falling from the rod were returned, to a
maximum of 10 falls/trial. The time to first fall and total
number of falls per trial were recorded. For longitudinal
accelerating rotarod assessment 4-, 8- or 12-month-old
mice were tested on a rod accelerating from 5 to 40
RPM over 300 seconds. Latency to fall from the rod was
recorded. 3 trials in 1 day were averaged to give mean
performance for each mouse at each age.
Acoustic startle and prepulse inhibition (PPI) were
measured in SR-LAB chambers (San Diego Instruments,
San Diego, USA). Before use, the chambers were cali-
brated using a vibrating standardization unit at 700 V
(San Diego Instruments, San Diego, USA). After a 5-
minute acclimatization period mice were exposed to 100
50 ms startle stimuli with intensities ranging from back-
ground level (70 dB) to 120 dB. Startle stimuli were pre-
sented in pseudorandomized order in 10 blocks of 10
trials, with a pseudorandomized 8-32 second inter-trial
interval.
For the PPI task, the “pulse” was a 40 ms 120 dB sti-
mulus. Eight blocks of trials were conducted-the first
and last of which were a series of 6 pulse only trials.
The first block was used to determine the average startle
intensity. The subsequent 6 blocks consisted of 6 trials:
70 dB (background) alone ("no-pulse”), 120 dB for 40
ms alone ("pulse”) and 4 pre-pulse trials with pre-pulse
intensities of 72, 74, 78 and 86 dB (20 ms duration, pre-
pulse interval of 100 ms). PPI was calculated as: [(First
120 dB block response)-(PPI block response)]/(First 120
dB block response). PPI stimuli were presented in pseu-
dorandomized order with a 8-32 second inter-trial
interval.
For the swimming T-maze + reversal task mice were
tested in a white acrylic maze with arm dimensions 38
× 14 cm [37]. The maze was filled with water and a
platform (10 × 14 cm) submerged below the water sur-
face in one arm of the maze. Mice were released at the
base of the stem of the T and learned to swim to the
submerged platform-the time to platform, total number
of arm entries and arm re-entries were recorded. For
training, mice received 4 trials per day for 3 days (12
total trials) with a 45-minute inter-trial interval. On the
5th day, the platform was switched to the opposite arm
of the maze and mice were required to change strategies
to find the platform in its new location. Mice received 4
trials with a 45-minute inter-trial interval.
For the spontaneous alternation task mice were tested
in the maze described above for the swimming T-maze
task without water. A dividing wall was placed at the
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Page 9 of 12intersection of the T extending into the stem of the T to
encourage entry into a single goal arm. Mice were
placed at the base of the T and allowed to choose a goal
arm. A barrier was then lowered to prevent exit from
the goal arm during a 1 minute exploration interval dur-
ing which the central divider was removed. Mice were
then removed from the explored goal arm and immedi-
ately placed at the base of the T and once again allowed
to choose a goal arm. Mice who entered the previously
explored goal arm were given a score of 0 while mice
who entered the novel arm were given a score of 1.
For the open field exploration task mice were tested in
a gray acrylic open topped box with dimensions 50 × 50
× 20 cm under bright lighting. Mice were placed in the
corner of the box and allowed to explore for 10 min-
utes. Trials were recorded using a ceiling mounted
video camera and exploration tracks were analyzed
using EthoVision XT 7.0 software (Noldus).
Pathology, including MRI
Mice were terminally anesthetized by intraperitoneal
injection of 2.5% avertin, and transcardially perfused
with 30 mL phosphate buffered saline, followed by 30
mL 4% ice-cold paraformaldehyde in PBS. Testes were
dissected out and weighed after fixation. Heads were
removed and skin, lower jaws ears and cartligenous nose
tip dissected away. Skulls were post-fixed in 4% parafor-
maldehyde at 4°C overnight. Skulls were soaked in PBS
+ 0.01% NaAzide for 5 days at room temperature with
rotation. Skulls were then enhanced in PBS + 0.02%
NaAzide with 2 mM Prohance (Bracco Diagnostics, DIN
02229056). A 7.0 Tesla MRI scanner (Varian Inc., Palo
Alto, CA) with a 6 cm inner bore diameter insert gradi-
ent set was used for all MRI scans. Parameters used for
anatomical MRI scans were optimized for high efficiency
and gray/white matter contrast: T2-weighted, 3D fast
s p i ne c h o ,w i t haT Ro f3 2 5m s ,a n dT E so f1 0m sp e r
echo for 6 echoes, four averages, field-of-view of 14 ×
14 × 25 mm
3 and matrix size of 432 × 432 × 780 giving
an image with 0.032 mm isotropic voxels. Total imaging
time for this MRI sequence is ~12 hours [61]. Volumes
were then automatically segmented into 62 separate
anatomical structures using automated image registra-
tion techniques [62-64]. For graphing, volumes were
standardized and expressed as Z-scores. After imaging
skulls were removed and brains weighed.
Statistics
For data with one independent variable an unpaired t-
test or one-way ANOVA model was fitted and tested (as
appropriate), followed by Newman-Keuls or Bonferroni
post-hoc tests. Data with two or more independent vari-
ables was analyzed by two-way ANOVA. To control for
repeated measurements and other sources of correlated
error data were analyzed using repeated measures two-
w a yA N O V Ao r ,w h e nv a l u e sw e r em i s s i n g ,b yf i t t i n ga
linear mixed effects (LME) model, followed by analysis
of variance testing. In LME models, each mouse was
assigned a random intercept. T-tests, one- and two-way
ANOVA’s were performed using Prism 4.0 software,
and linear mixed effects models were done using the R
language and environment including the “nlme” linear
mixed effects model package [65].
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